Rentschler Biopharma is in the process of expanding its 2,000-liter bioreactor production capacity at its site in Germany. Germany is second only to the U.S. in terms of the number of manufactured biopharmaceutical active ingredients approved in the EU, however the country is falling behind in a global comparison of production capacity, ranking fifth in 2021.   “For most biopharmaceuticals currently in development, this size of bioreactor offers maximum flexibility for both clinical- and...